Abstracts tagged "etanercept and rheumatoid arthritis (RA)"

Abstract Number: 1843 • 2014 ACR/ARHP Annual Meeting
Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
Noortje van Herwaarden¹, Aatke van der Maas¹, Michiel Minten¹, Frank H.J. van den Hoogen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Bart van den Bemt⁵ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ³Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose TNF inhibitors (TNFi) have proven to be effective in the treatment of rheumatoid arthritis (RA). They are however associated with side effects and high…
Abstract Number: 500 • 2014 ACR/ARHP Annual Meeting
Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement
Noortje van Herwaarden¹, Chantal Bouman², Aatke van der Maas³, Ronald F. van Vollenhoven⁴, Johannes W.J. Bijlsma⁵, Frank H.J. van den Hoogen⁶, Alfons A. den Broeder¹ and Bart van den Bemt⁷, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁷Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity…
Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Satoru Kodama, Satoshi Ito, Akira Murasawa, Kiyoshi Nakazono and Daisuke Kobayashi, Niigata Rheumatic Center, Shibata, Japan
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…
Abstract Number: 386 • 2014 ACR/ARHP Annual Meeting
Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis
Ute I. Schwarz¹, Janet E. Pope², Edward Keystone³, Boulos Haraoui⁴, Carter Thorne⁵, Yun-Hee Choi¹, Melanie Poulin-Costello⁶, Nabil Bayan⁷ and Richard B. Kim¹, ¹Western University, London, ON, Canada, ²Medicine, Western University, London, ON, Canada, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Montreal Hospital Centre, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁷Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose : In the CAnadian Methotrexate and Etanercept Outcome Study (CAMEO) continued therapy with etanercept (ETN) and methotrexate (MTX) led to better outcomes at month…
Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Paola de Pablo¹, Fiona M. Maggs², David Carruthers³, Abdul A. Faizal⁴, Mark T. Pugh⁵ and Paresh Jobanputra⁶, ¹Rheumatology, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, University of Birmingham, College of Medical & Dental Sciences, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ²Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ³Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, UK, Birmingham, United Kingdom, ⁴Department of Rheumatology, Solihull Hospital, Heart of England NHS Foundation Trust, UK, Solihull, United Kingdom, ⁵Department of Rheumatology, Saint Mary's Hospital, UK, Isle of Wight, United Kingdom, ⁶Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK., Birmingham, United Kingdom
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…
Abstract Number: 1886 • 2013 ACR/ARHP Annual Meeting
Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis
Amy Webster¹, Darren Plant², Mark Lunt³, Stephen Eyre⁴, Edward Flynn⁴, Paul Martin⁵, A. G. Wilson⁶, A. W. Morgan⁷, John Isaacs⁸, Jane Worthington^1,9 and Anne Barton^2,4, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁶Genomic Medicine, The University of Sheffield, Sheffield, United Kingdom, ⁷Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁸National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁹The University of Manchester, Manchester, United Kingdom
Background/Purpose: The introduction of biologic drug therapies targeting specific components of the inflammatory response represents a huge advance in the treatment of rheumatoid arthritis (RA).…
Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Arthur N. Lau¹, Alpesh Shah², Melissa Deamude³, Cynthia Mech⁴, Robert Bensen⁵ and William G. Bensen⁶, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Hsin-Hua Chen^1,2, Der-Yuan Chen¹, Chao-Hsiung Tang³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Nicole Huang⁵, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Taipei Medical University, Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…
Abstract Number: 999 • 2013 ACR/ARHP Annual Meeting
Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting
Ning Wu¹, Yuan-Chi Lee², Neel Shah³ and David J. Harrison³, ¹Economic Analysis and Solutions, United BioSource Corporation, Lexington, MA, ²United BioSource Corporation, Lexington, MA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Of the seven biologics FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) as of August 2011, etanercept, adalimumab, certolizumab, and golimumab…
Abstract Number: 1001 • 2013 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis
Vernon F. Schabert¹, Jason Yeaw², Jonathan Korn¹, Caroleen Quach³, David J. Harrison⁴, Huifeng Yun⁵, George Joseph⁶, David H. Collier⁴ and Jeffrey R. Curtis⁷, ¹IMS Health, Alexandria, VA, ²IMS Consulting Group, Alexandria, VA, ³Public Health Policy and Management, University of North Carolina at Chapel Hill, Gillings School of Public Health, Chapel Hill, NC, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Former Amgen Employee, Thousand Oaks, CA, ⁷Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL
Background/Purpose: Previous work compared one-year cost per effectively treated patient with biologics for rheumatoid arthritis (RA) using a published, claims-based algorithm.1 Longer term comparisons are…
Abstract Number: 487 • 2013 ACR/ARHP Annual Meeting
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
Richard CJ Campbell¹, Emma Sanders¹, Francesca Leone¹, Emma Gilgeours¹, Margaret Sibley¹ and Patrick D. Kiely², ¹Rheumatology, St George's Hospital, London, United Kingdom, ²Rheumatology Dept, St George's Hospital, London, United Kingdom
Background/Purpose: Clinical trials have previously demonstrated that it is safe and effective for some rheumatoid arthritis (RA) patients with low disease activity on full dose…
Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting
Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Diane Sauvageau³, Jean Pierre Pelletier¹, Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…
Abstract Number: 1287 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
James R. O'Dell¹, Ted R. Mikuls², Thomas Taylor³, Vandana Ahluwalia⁴, Mary Brophy⁵, Stuart Warren⁶, Robert Lew⁵, Ciaran Phibbs⁷, Aslam H. Anis⁸, Amy C. Cannella⁹, Gary A. Kunkel¹⁰, Alan R. Erickson², Edward Keystone¹¹ and the CSP551 RACAT Research Group¹², ¹Dept of Internal Medicine, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Medical Center, White River Junction, VT, ⁴William Osler Health Center, Brampton, ON, Canada, ⁵VA Boston Heathcare System, Boston, MA, ⁶VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁷Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, ⁸Population and Public Health, Univ of British Columbia, Vancouver, BC, Canada, ⁹Divison of Rheumatology, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ¹⁰Div of Rheumatology, George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Boston, MA
Background/Purpose: Double-blind placebo controlled randomized trials have demonstrated the efficacy of 15 different therapies in RA patients with active disease despite methotrexate (MTX). No blinded…
Abstract Number: 477 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis
Jiunn Horng Chen¹ and Wen-Miin Liang², ¹Internal Medicine, China Medical University Hospital, Taichung City, Taiwan, ²Biostatistics Center, China Medical University, Taichung, Taiwan
Background/Purpose: The recent Taiwanese report has indicated an elevated risk of malignancy in RA patients1. Etanercept, one of the tumor necrotic factor inhibitors (TNF-I) to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].